ENTA/NVS—EDP-239/Alisporivir: ph2 DDI in healthy volunteers started Jun 2014; ph2b in combination in HCV patients will start after completion of DDI study.
GILD—Sovaldi/Ledipasvir: PDUDA date 10/10/14; approved by EU’s CHMP 9/26/14, awaiting rubber-stamping by EU Commission.
GILD—TAF (replacement for Viread in HIV combinations): top-line data from treatment-naïve ph3 reported 9/24/14; NDA/MAA submissions 4Q14.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.